93 results about "Sphingomyelin" patented technology

The present invention provides a Lactiplantibacillus plantarum ( Lactiplantibacillus plantarum ), strain 24, which is deposited in the China General Microbiological Culture Collection Center, deposit number: CGMCC No. 31278. The Lactiplantibacillus plantarum 24 of the present invention can secrete sphingomyelinase to promote the production of ceramide in HaCaT cells; Lactiplantibacillus plantarum 24 or its metabolite or its lysate can up-regulate the expression of key enzymes in the sphingomyelinase and / or ceramide synthesis pathway of skin cells, repair the skin barrier; down-regulate the expression of pro-inflammatory cytokines, inhibit autophagy, and has a good anti-inflammatory effect; at the same time, it also has good antioxidant and whitening effects. The Lactiplantibacillus plantarum 24 or its metabolite or its cell lysate of the present invention can be used in the preparation of products having the above-mentioned effects or functions.

A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The invention introduces novel chemical modifications to sphingomyelin and ceramide molecules, making them readily available for targeted staining and detection techniques, such as click chemistry.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The invention provides a nutritional composition capable of influencing protein expression of brain hippocampus and application of the nutritional composition. The nutritional composition of the present invention comprises sialic acid, sphingomyelin and phosphatidylcholine, in which the ratio of the sum of the contents of sphingomyelin and phosphatidylcholine to the content of sialic acid is 1: 1 by weight, and the ratio of sphingomyelin to phosphatidylcholine is 0.2: 1 to 1.4: 1 based on the total weight of sphingomyelin and phosphatidylcholine. The composition can increase the gray matter volume of the brain and can improve the expression of BDNFmRNA of the hippocampus and the prefrontal cortex.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The invention relates to a composition containing anti-wrinkle lipidosome for cosmetic preparation and a preparation method of the composition, and belongs to the technical field of cosmetics. The invention discloses a composition containing anti-wrinkle lipidosome and a preparation method thereof. The composition comprises four plant extracts of purple coneflower, calendula officinalis, salvia officinalis and elderberry, and lipidosome consisting of lecithin, cholesterol, sphingomyelin and ascorbyl palmitate, and is supplemented with components such as a humectant and an emulsifier. According to the composition, through the synergistic effect of the plant extract and the lipidosome, the anti-wrinkle effect is enhanced, and the storage and illumination stability is improved; an extract structure is optimized by a compound fermentation process, and a liposome system is adapted; the components are safe and suitable for multiple skin types, the preparation process is compatible with industrial production, and the pain points that traditional anti-wrinkle products are poor in stability and insufficient in effect are solved.

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.

The application provides a kind of primary neuron cell golgi staining method and application based on lipid, comprising the following steps: 1) extracting, culturing and fixing primary neuron cell;2) selecting one kind of lipid in phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, cholesterol, lecithin;3) the selected lipid is evenly covered on the cell surface, and Golgi staining solution is added for staining;4) remove Golgi staining solution, and use reducing agent for developing reaction;5) optical microscope imaging observation and / or simultaneous radiation X-ray imaging observation;6) the imaging data is analyzed and processed using data processing software.The application successfully stains primary neuron cell, and under the simultaneous radiation X-ray imaging technology, neuron dendrite and morphology can be observed, which lays a good research foundation for using simultaneous radiation X-ray to quantitatively study neuron complete three-dimensional structure and complete three-dimensional fine structure of neuron.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition in which liposomes encapsulate a drug with an immune checkpoint inhibitor. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin, and cholesterols, the liposome composition includes a drug and has art inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

The present invention relates to the field of nutritional compositions, methods of providing nutritional compositions and uses thereof. More particularly, the present invention relates to a ready-to-eat powdered infant formula or ready-to-eat powdered growth formula exhibiting desirable gastric digestion characteristics. There is provided a nutritional composition comprising casein, whey protein comprising alpha-lactalbumin (aLac) and beta-lactoglobulin (bLac), and protein-coated fat droplets wherein the composition has a protein content of from 5% to 20% (w / w) based on total solids; the bLac content is at least 3% (w / w) based on the total protein level, and the aLac + bLac content is at least 25% (w / w) based on the total protein level; the fat content is in the range of 10% to 50% (w / w) based on total solids; the fat droplets are coated with an average protein load of 2 to 10 mg / m2, and wherein the weight ratio of casein: (aLacc + bLac) on the fat droplets is at least 4 times the weight ratio of casein: (aLacc + bLac) in the total composition; the level of sphingomyelin per 100 g of the composition is between 70 mg and 200 mg; the level of phospholipids per 100 g of the composition is between 280 mg and 950 mg.

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention provides a nutritional composition especially well suited as an infant nutritional composition, but also as a nutritional support product for pregnant women and as senior nutritional supplement, where phosphatidylcholine and sphingomyelin, and thus choline, also are highly relevant. The present invention provides a nutritional composition which contains choline of high bio-availability.

The invention provides lipid rich in sphingomyelin, a preparation method and a phospholipid ingredient for infant formula milk powder, and relates to the technical field of dairy product processing.The lipid rich in sphingomyelin and the preparation method thereof have the advantages that primary separation is carried out by the aid of supercritical carbon dioxide extraction technologies, secondary extraction is carried out by the aid of follow-up ethyl alcohol serving as entrainer, non-polar lipid can be effectively removed, and the lipid rich in sphingomyelin can be obtained; and phospholipids with high polarity, especially sphingomyelin, are retained. The ethanol concentration is controlled to be 20% (v / v), so that the solubility and the selective extraction efficiency of lipid rich in sphingomyelin are improved, and a higher sphingomyelin enrichment degree is realized in a final product. Meanwhile, ethanol extraction can be directly combined with a freezing crystallization method, other organic solvents are not introduced into the method, the method is green and safe, complex equipment support is not needed, the technological process is short, operation is easy and convenient, cost is low, and the method is suitable for rapid preparation.

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.

The invention discloses a method for producing phosphatidylserine through enzyme catalysis, and belongs to the technical field of biology, and the method specifically comprises the following steps: in a reaction system of a [BMIM] [BF4] aqueous solution, taking natural phospholipid containing phosphatidylcholine and cephalin as a raw material, adding L-serine, calcium salt and phospholipase D, and carrying out a trans-acylation reaction. By introducing cephalin (4%-10%, preferably 6%-8%) and sphingomyelin (5%-10%) in a specific proportion and combining with a [BMIM] [BF4] ionic liquid system, high efficiency and high purity (the purity gt, 79.6% and the yield gt, 76.4%) of PS production are realized, and the problem that the yield and the purity cannot be considered at the same time in the traditional process is thoroughly solved.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

The invention discloses a phospholipid hydrophilic chromatographic separation and evaporative light scattering detection method suitable for liquid milk, milk powder and milk source raw materials. The method comprises the following steps: preparing a sample solution from a sample to be detected; extracting the sample solution by using a solution of chloroform and methanol to obtain subnatant as extract liquor; adding a saturated salt solution into the extract liquor for chromatographic purification, and taking separated lower clear liquid as purified liquid; preparing the purified liquid into a sample introduction liquid; and determining the phospholipid content in the sample injection solution by using a liquid chromatography-evaporative light scattering detector. In the detection method, a sample solution is extracted by using a solution of chloroform and methanol, and a saturated salt solution is added into an extraction solution for chromatographic purification, so that chromatographic peaks are not interfered, and various phospholipids in food can be accurately measured at the same time; the method can be used for simultaneously determining phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidylserine and phosphatidylinositol in food, and has the advantages of simplicity, rapidness, accuracy, low detection limit and high sensitivity.

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

To provide a mixture for use in the treatment of hypotension in a human subject having sepsis.SOLUTION: The mixture comprises: (a) a first empty liposome comprising cholesterol, wherein an amount of cholesterol is 45% to 55% (weight per weight) and the liposome does not incorporate a pharmaceutical drug; and (b) a second empty liposome comprising sphingomyelin, wherein the liposome does not incorporate a pharmaceutical drug. The mixture is administered to the human subject in at least two doses, including a first dose and a second dose, with an interval of 6 to 96 hours between the first dose and the second dose.SELECTED DRAWING: None

The invention relates to the technical field of biological pharmacy, and discloses a mesenchymal stem cell exosome enhancer and a preparation method thereof, the enhancer is composed of purified mesenchymal stem cell exosome, a functional lipid complex, cytokine sustained release microspheres, a targeting modifier, a stabilizer and a penetration enhancer according to specific parts by weight. The preparation method comprises the following steps: obtaining a high-activity exosome by combining ultracentrifugation with size exclusion chromatography purification; preparing a functional lipid complex composed of cholesterol, sphingomyelin and phosphatidylserine to promote membrane fusion; preparing a sodium alginate-chitosan sustained release microsphere loaded with a basic fibroblast growth factor and a transforming growth factor-beta1; synthesizing an RGD peptide modified hyaluronic acid targeting modifier; and finally, mixing the components, filtering and sub-packaging. The quality fluctuation risk of subsequent preparation preparation is reduced, and it is guaranteed that the final reinforcing agent product has a highly uniform structure.

The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.

The invention discloses lactobacillus crispatus CCFM1462 and application of a metagen of the lactobacillus crispatus CCFM1462 in promoting skin ceramide synthesis by regulating a sphingomyelinase pathway, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 provided by the invention can effectively improve the content of ceramide in the aspects of external use and oral administration. According to the application disclosed by the invention, it is found that a metagen (fermented supernatant CCFM1462-S) prepared by oral administration of lactobacillus crispatus CCFM1462 can promote expression of sphingomyelinase, so that a sphingomyelinase pathway in a ceramide synthesis process is regulated and controlled, and rapid supplement of ceramide is realized. Therefore, the lactobacillus crispatus plays a crucial role in solving the problem that ceramide needs to be supplemented emergently after skin irritation, has a huge application prospect when being applied to oral or external medicines, and is used for transient stress repair of skin.